CYCLERION THERAPEUTICS, INC. Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share
CYCLERION THERAPEUTICS, INC. (CYCN) reported Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share of $0.00 per share for the 12-month period ending 2024-12-31, per its 10-K/A filed 2025-11-12.
Financial Statements › Income Statement › Net Income
us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare · last filed 2025-11-12
- CYCLERION THERAPEUTICS, INC. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- CYCLERION THERAPEUTICS, INC. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for the quarter ending 2024-06-30 was $0.00.
- CYCLERION THERAPEUTICS, INC. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for the quarter ending 2024-03-31 was $0.00.
- CYCLERION THERAPEUTICS, INC. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for the quarter ending 2023-09-30 was $5.53.
- CYCLERION THERAPEUTICS, INC. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- CYCLERION THERAPEUTICS, INC. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for fiscal 2023 was $3.14.
- CYCLERION THERAPEUTICS, INC. income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for fiscal 2022 was -$11.89.
| Period end | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share 3 month | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share 6 month | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share 9 month | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 10-K/A · filed 2025-11-12 | |||
| 2024-09-30 | $0.00 10-Q · filed 2024-11-14 | $0.00 10-Q · filed 2024-11-14 | ||
| 2024-06-30 | $0.00 10-Q · filed 2024-08-07 | $0.00 10-Q · filed 2024-08-07 | ||
| 2024-03-31 | $0.00 10-Q · filed 2024-05-07 | |||
| 2023-12-31 | $3.14 10-K/A · filed 2025-11-12 | |||
| 2023-09-30 | $5.53 10-Q · filed 2024-11-14 | $3.19 10-Q · filed 2024-11-14 | ||
| 2023-06-30 | -$1.04 10-Q · filed 2024-08-07 | -$2.76 10-Q · filed 2024-08-07 | ||
| 2023-03-31 | -$1.73 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | -$11.89 10-K · filed 2024-03-05 | |||
| 2022-09-30 | -$2.80 10-Q · filed 2023-11-13 | -$10.56 10-Q · filed 2023-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |